Study design (if review, criteria of inclusion for studies)
double-blind trial
Participants
153 children with cystic fibrosis during the initial appearance of influenza A/England/42 virus in the New England area
Interventions
Amantadine-HC1
Outcome measures
symptomatic and biochemical toxicity
Main results
Infection with this variant strain of influenza virus did not reach epidemic proportions during the study, so that the effectiveness of amantadine in this study population could not be fully assessed. However, the potential symptomatic and biochemical toxicity of amantadine was carefully monitored in a pediatric population.
Authors' conclusions
Serologic screening by complement fixation tests indicated that respiratory viruses may be important pathogens in exacerbations of respiratory disease in patients with cystic fibrosis.